Generating revenues with synthetic biology like Red Hat does with Linux.

1. THIS
IS
NOT
AN
OFFERING
TO
BUY
OR
SELL
SECURITIES
Safe
Harbor
for
Forward-­‐Looking
Statements
Except for the statements of historical fact, the information presented herein constitutes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of
Microbial Robotics LLC (the “Company”) to be materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Such factors include general economic and business conditions,
the ability to fund operations, the ability to forge partnerships required for deployment, changes in consumer and corporate
buying habits, energy development, production, and distribution, the rapid pace of change in the technology industry and
other factors over which the Companies have little or no control. The Companies assume no obligation to publicly update or
revise any forward-looking statements. A full Risk Disclosure is available within the business plan.
Your advancement beyond this page or slide into this document indicates you read and understand this disclosure. The
remaining aspects of this document are confidential. The contents should not be disclosed beyond you without the
expressed written consent of the Company.
1

2. WITH SMALL
ORGANISMS
With an Open model, rapidly prototyping synthetic biology-based bacteria
and viruses for chemical, therapeutic, and water industry experts.
SOLVING BIG PROBLEMS
JASON E. BARKELOO, CEO

3. WHY OPEN SYNTHETIC BIOLOGY MODEL?
[11] United States Patent and Trademark Office, Patent Pools:A Solution to the Problem of Access in Biotechnology Patents? (Dec 5, 2000)
available at http://www.uspto.gov/web/offices/pac/dapp/opla/patentpool.pdf .The USPTO noted two of the most profitable in the biotechnology
area are those of Cohen and Boyer, which are owned by Stanford University. Stanford minimized licensing fees and extended non-exclusive
licenses.This discouraged would-be infringers since the cost of obtaining a license is low. Instead of encourage infringement and patent trolling,
the ease of non-exclusive licenses meant broad distribution and spurred further innovation. See also National Research Council, Intellectual
Property Rights and Research Tools in Molecular Biology (1996), available at http://www.nap.edu/readingroom/books/property/5.html.
“With respect to biologics commercialization, the U.S. Patent andTrademark Office
(USPTO) specifically noted the open (patent-pool) approach:
‘No single company or organization, however, has the resources to develop any
significant fraction of the genetic information present in an organism. If proprietary
information is not freely available or licensed in an affordable manner, researchers
will be precluded from using these protected nucleic acids to develop new
therapeutics and diagnostics. It would be, however, shortsighted of a patent holder
to demand such a prohibitively expensive licensing agreement that would preclude
anyone else from utilizing a patented invention. . . . By minimizing licensing fees and
extending non-exclusive licenses, potential infringers were inclined to obtain
licenses and the technology was therefore broadly distributed. . . .’[11]”

4. 20152014
NEW $MM1ST SUBSIDIARYFOUNDED
2009
OPPORTUNITY$MM EXIT 2014

5. YEARS
Pablo Pomposiello
PhD
Bacterial Physiology
Consultant
Timothy P. Cripe
MD, PhD
Oncolytics Consultant
Ravi N. Samy
MD, FACS
Chief Medical Officer
Jason E. Barkeloo
MA
Founder & CEO
Shengchang Su
PhD
Director
MicrobialBots and
GeRM Engineering
Li Guo
PhD
Director
Cellular
Engineering
Jay Springer
JD
Director
Regulatory
and Legal Affairs
Jin Kong
JD
Director
GlobalSynBio &
Open Therapeutics
EXPERIENCE
100+
K. Krishnamoorthy
MD
Chief Medical Officer
India

6. “Imagine a cancer cure
without the destructive side effects of chemotherapy.
This leader in pediatric research is doing just that.”

7. SUBSIDIARIES
PRODUCTS
NON-OPERATING
PLATFORMS
CONSUMABLES
SUBSIDIARIES

8. BactoBots
ViruBots
PLATFORMS

9. WHY NOW?
$18B
$9B
2008 2012 2016
Research and Markets, May 2014
2013
2020
CAGR
$3 BILLION
$40 BILLION
44%

10. Can’t ship GMOs Across borders
Can’t Ship GMOs across borders
1ST BOTTLENECK

11. Ship GeRM, consumables, and knowledge across borders, not GMOs.
1ST BOTTLENECK SOLVED

12. http://csdd.tufts.edu/news/complete_story/pr_tufts_csdd_2014_cost_study

13. 2ND BOTTLENECK SOLVED
Focus on Rapid ROI
t 12 months 5 years
Clinical trials
Productization
expert
MARKETS
Rapid prototyping
Open Therapeutics

14. Exit Zone
5 years
aquaculture denitrification (DeNitro Water)
gold precipitate (Aureus Water)
NON-OPERATING SUBSIDIARY PIPELINE
aquaculture probiotic (Fish Probiotic)
cholesteatoma lytic (Auricle Solutions)
breast cancer (Pectus Lytics)
neuroblastoma (Neurolytics)
cancer screen (LightOwl Biomarkers)
cholesteatoma lytic (AureMed)
12 months

15. SUBSIDIARY ACQUIRERSalso competitors
water chemicals therapeutics
WASTE WATER-TO-VALUE FUELS & BUILDING BLOCKS ANTIBIOTICS & ONCOLYTICS

16. PROJECTIONS
Very low cost to scale
Break-even
2015 2016 2017 2018 2019
Net Income $(433,884) $4,456,716 $11,129,052 $18,130,972 $32,300,094
Net Margin -12% 32% 44% 49% 54%
EBITDA $(619,400) $6,540,600 $16,174,200 $26,478,400 $46,841,200
EBITDA (Percent) -16% 48% 64% 71% 79%

17. Subsidiary Exits
Revenues
Operations
$3,000,000
WITH

18. ONE OTHER THING…

19. http://www.eetimes.com/document.asp?doc_id=1325390
GIANTS
TRYING TO
CATCH-UP
TO MICROBIAL
ROBOTICS”
“

20. TEAM
PRODUCTS
MARKETS
EXIT ROIs
JASON E. BARKELOO, CEO
jason@MicrobialRobotics.com
+1.513.225.8765